See more : FRMO Corporation (FRMO) Income Statement Analysis – Financial Results
Complete financial analysis of Enanta Pharmaceuticals, Inc. (ENTA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Enanta Pharmaceuticals, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Critical Solutions, Inc. (CSLI) Income Statement Analysis – Financial Results
- Industrial and Commercial Bank of China Limited (ICK.VI) Income Statement Analysis – Financial Results
- BB Liquidating Inc. (BLIBQ) Income Statement Analysis – Financial Results
- Shenzhen Jdd Tech New Material Co Ltd Ordinary Shares – Class A (301538.SZ) Income Statement Analysis – Financial Results
- Galenica AG (GALE.SW) Income Statement Analysis – Financial Results
Enanta Pharmaceuticals, Inc. (ENTA)
About Enanta Pharmaceuticals, Inc.
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus. Enanta Pharmaceuticals, Inc. was founded in 1995 and is headquartered in Watertown, Massachusetts.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 67.64M | 79.20M | 86.16M | 97.07M | 122.47M | 205.20M | 206.63M | 102.81M | 88.27M | 160.88M | 47.74M | 32.05M | 41.71M | 41.88M | 22.76M |
| Cost of Revenue | 0.00 | 0.00 | 2.97M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 67.64M | 79.20M | 83.19M | 97.07M | 122.47M | 205.20M | 206.63M | 102.81M | 88.27M | 160.88M | 47.74M | 32.05M | 41.71M | 41.88M | 22.76M |
| Gross Profit Ratio | 100.00% | 100.00% | 96.55% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| Research & Development | 131.48M | 163.52M | 164.52M | 174.11M | 136.76M | 142.21M | 94.86M | 57.45M | 40.46M | 23.19M | 18.74M | 16.84M | 15.12M | 11.55M | 9.72M |
| General & Administrative | 57.85M | 52.89M | 45.48M | 32.54M | 27.36M | 26.25M | 23.44M | 20.75M | 16.97M | 13.54M | 10.02M | 6.18M | 5.30M | 0.00 | 6.11M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 57.85M | 52.89M | 45.48M | 32.54M | 27.36M | 26.25M | 23.44M | 20.75M | 16.97M | 13.54M | 10.02M | 6.18M | 5.30M | 5.04M | 6.11M |
| Other Expenses | 0.00 | 0.00 | 83.00K | 1.99M | 6.62M | 8.82M | 4.79M | 2.33M | 1.72M | 1.31M | 283.00K | 598.00K | 0.00 | 5.04M | 309.00K |
| Operating Expenses | 189.33M | 216.41M | 210.00M | 206.65M | 164.11M | 168.46M | 118.30M | 78.20M | 57.43M | 36.73M | 28.76M | 23.02M | 20.42M | 16.58M | 15.82M |
| Cost & Expenses | 189.33M | 216.41M | 210.00M | 206.65M | 164.11M | 168.46M | 118.30M | 78.20M | 57.43M | 36.73M | 28.76M | 23.02M | 20.42M | 16.58M | 15.82M |
| Interest Income | 14.77M | 11.36M | 1.57M | 2.02M | 6.47M | 8.82M | 0.00 | 2.53M | 1.74M | 968.00K | 467.00K | 248.00K | 118.00K | 83.00K | 14.00K |
| Interest Expense | 10.94M | 5.15M | 1.57M | 0.00 | 0.00 | 8.82M | 4.85M | 40.00K | 45.00K | 8.00K | 18.00K | 31.00K | 0.00 | 3.16M | 0.00 |
| Depreciation & Amortization | 2.34M | 2.37M | 2.97M | 3.33M | 3.64M | 3.26M | 2.52M | 2.14M | 1.66M | 639.00K | 352.00K | 221.00K | 172.00K | 499.00K | 553.00K |
| EBITDA | -104.51M | -123.48M | -119.22M | -104.25M | -38.00M | 40.00M | 90.85M | 26.75M | 32.50M | 124.79M | 19.34M | 9.25M | 21.57M | 26.97M | 8.30M |
| EBITDA Ratio | -154.52% | -155.90% | -140.38% | -112.88% | -34.00% | 17.90% | 42.75% | 23.94% | 34.94% | 77.17% | 39.77% | 28.17% | 51.74% | 61.80% | 34.35% |
| Operating Income | -121.69M | -137.21M | -123.84M | -109.57M | -41.64M | 36.74M | 88.33M | 24.61M | 30.84M | 124.15M | 18.99M | 9.03M | 21.29M | 25.30M | 6.94M |
| Operating Income Ratio | -179.92% | -173.23% | -143.74% | -112.88% | -34.00% | 17.90% | 42.75% | 23.94% | 34.94% | 77.17% | 39.77% | 28.17% | 51.05% | 60.41% | 30.50% |
| Total Other Income/Expenses | 3.90M | 6.21M | 1.66M | 1.99M | 6.62M | 8.82M | 4.79M | 2.33M | 1.72M | 1.31M | 283.00K | 598.00K | 110.00K | -1.99M | 805.00K |
| Income Before Tax | -117.79M | -131.00M | -122.19M | -107.58M | -35.02M | 45.56M | 93.12M | 26.95M | 32.56M | 125.46M | 19.27M | 9.63M | 21.40M | 23.31M | 7.75M |
| Income Before Tax Ratio | -174.15% | -165.39% | -141.82% | -110.82% | -28.59% | 22.20% | 45.07% | 26.21% | 36.89% | 77.98% | 40.36% | 30.03% | 51.31% | 55.66% | 34.03% |
| Income Tax Expense | -1.74M | 2.82M | -433.00K | -28.58M | 1.15M | -826.00K | 21.17M | 9.24M | 10.89M | 46.46M | -15.17M | -221.00K | 0.00 | 3.16M | -157.00K |
| Net Income | -116.05M | -133.82M | -121.76M | -79.00M | -36.17M | 46.38M | 71.96M | 17.71M | 21.67M | 78.99M | 34.44M | 9.63M | 21.40M | 23.31M | 7.90M |
| Net Income Ratio | -171.58% | -168.95% | -141.31% | -81.38% | -29.53% | 22.60% | 34.82% | 17.23% | 24.55% | 49.10% | 72.14% | 30.03% | 51.31% | 55.66% | 34.72% |
| EPS | -5.48 | -6.38 | -5.91 | -3.92 | -1.81 | 2.37 | 3.48 | 0.93 | 1.14 | 4.23 | 1.88 | -0.67 | 1.18 | 1.35 | 0.02 |
| EPS Diluted | -5.48 | -6.38 | -5.91 | -3.92 | -1.81 | 2.21 | 3.48 | 0.91 | 1.13 | 4.09 | 1.80 | -0.67 | 0.52 | 0.59 | 0.02 |
| Weighted Avg Shares Out | 21.16M | 20.97M | 20.60M | 20.17M | 19.94M | 19.58M | 20.65M | 19.07M | 18.93M | 18.67M | 18.36M | 9.79M | 1.16M | 1.16M | 12.75M |
| Weighted Avg Shares Out (Dil) | 21.16M | 20.97M | 20.60M | 20.17M | 19.94M | 20.97M | 20.65M | 19.41M | 19.22M | 19.30M | 19.19M | 9.79M | 2.64M | 2.64M | 14.13M |
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter with Conference Call and Webcast Today at 4:30 p.m. ET
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections, today reported financial results for its fiscal third quarter ended June 30, 2023. “Our fiscal third quarter was marked by important...
Enanta Pharmaceuticals to Host Conference Call on August 7 at 4:30 p.m. ET to Discuss its Financial Results for Its Fiscal Third Quarter Ended June 30, 2023
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections, today announced that it plans to report its financial results for its fiscal third quarter ended June 30, 2023 after...
Enanta Pharmaceuticals shares gain after RSV treatment shows positive results in early trial
Shares of Enanta Pharmaceuticals Inc. ENTA, -0.25% gained 5% premarket on Tuesday after the biotech company released positive results from an early-phase clinical trial of a treatment for respiratory syncytial virus, or RSV. EDP-323, an oral antiviral that received Food...
Enanta Pharmaceuticals Announces Positive Data From a Phase 1 Clinical Study of EDP-323, an Oral, L-Protein Inhibitor in Development for the Treatment of Respiratory Syncytial Virus
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating novel, small molecule drugs for viral infections, today announced positive topline data from a Phase 1 study assessing the safety, tolerability, and pharmacokinetics (PK) of orally...
Enanta Pharmaceuticals Announces Data Presentation at the European Association for the Study of the Liver (EASL) International Liver Congress™ 2023
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections, today announced that preclinical data from Enanta's out-licensing portfolio has been accepted for a poster presentation at the European Association for...
Enanta Pharmaceuticals to Participate at Jefferies Global Healthcare Conference
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections, today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, will participate in a fireside chat at Jefferies Global...
Enanta Pharmaceuticals (ENTA) Reports Q2 Loss, Misses Revenue Estimates
Enanta Pharmaceuticals (ENTA) came out with a quarterly loss of $1.79 per share versus the Zacks Consensus Estimate of a loss of $1.91. This compares to loss of $1.63 per share a year ago.
Enanta Pharmaceuticals Reports Positive Topline Results from Phase 2 SPRINT Trial Evaluating EDP-235 in Standard Risk Patients with COVID-19
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections, today announced topline data from SPRINT (SARS-Cov-2 PRotease INhibitor Treatment), a double-blind, placebo-controlled Phase 2 clinical trial of EDP-235, Enanta's...
Enanta Pharmaceuticals Reports Positive Topline Results from Phase 2 SPRINT Trial Evaluating EDP-235 in Standard Risk Patients with COVID-19
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections, today announced topline data from SPRINT (SARS-Cov-2 PRotease INhibitor Treatment), a double-blind, placebo-controlled Phase 2 clinical trial of EDP-235, Enanta’s...
Enanta Pharmaceuticals to Host Conference Call on May 8 at 4:30 p.m. ET to Discuss its Financial Results for its Fiscal Second Quarter Ended March 31, 2023
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections, today announced that it plans to report its financial results for its fiscal second quarter ended March 31, 2023 after...
Source: https://incomestatements.info
Category: Stock Reports